ACR 2021

New treatment alternative in GCA: promising secukinumab data

IL-17 pathway important for pain in PsA

Dear Doctor: JAKi risk factors and safety profile - is there a class-effect?

axPsA is axSpA is not...!?

Pulmonary involvement and possible therapy concepts in RA

ARIAA: prevention study or very early treatment of RA?

No need for methotrexate in ustekinumab treatment in PsA

Should we use ultra-low-dose rituximab during the pandemic?

Discordance between patients and physicians in RA

Abatacept may reduce subclinical inflammation in RA-at risk patients

We need predictors of response for RA treatment

Tofacitinib is associated with a slightly increased risk of cancer

Cardiovascular disease in RA

Nausea & alopecia with MTX in RA

Long awaited - MACE data from ORAL surveillance

Statins reduce cardiovascular risk and​ mortality - with a slight increase in type 2 diabetes risk

Cycling JAKi compared to switching to biologic DMARD in patients with RA

Désaccords patient/Médecin : se comprendre pour plus d'efficacité

Tofacitinid se asocia con un ligero incremento del riesgo de cáncer​

Lange erwartet - MACE-Daten zur ORAL Surveillance

Quels effets indésirables peuvent être associés à la prise de MTX ?

Skifte mellom JAK hemmere sammenliknet med skifte til biologisk DMARD hos pasienter med RA

Quels marqueurs de réponse aux traitements dans la vraie vie ?

Abatacept reduce la inflamación subclínica en pacientes con artralgia con riesgo de progresión a artritis reumatoide

Las estatinas reducen el riesgo cardiovascular y la mortalidad, con un ligero aumento en el riesgo de diabetes tipo 2

Comparison of composit indices for disease activity in PsA patients

PET/CT in diagnosis for PsA

Guselkumab: the better ustekinumab?!

Guselkumab in axial symptoms

Joint effusions and enthesitis after physical exertion

Pain differs: Superior effect of IL-17-inhibition vs. TNF in PsA patients with uncontrolled inflammation

Anemia is an issue in PsA - proper treatment possible!

Upadacitinib in PsA

Secukinumab vs TNF-α blockers in enthesitis

No need for MTX in ustekinumab-treated patients

Tildrakizumab in PsA

Prediction of psoriatic arthritis in patients with psoriasis using DNA methylation profiles

Osteoporosis in PsA

Axial PsA MRI data

Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events

Guselkumab: das bessere Ustekinumab?!

Previsione di sviluppo di artrite psoriasica in pazienti con psoriasi utilizzando profili di metilazione del DNA

Guselkumab bei axialer Symptomatik

Tildrakizumab bei PsA

Studio di confronto tra i vari indici compositi per la valutazione di attività di malattia nell'Artrite Psoriasica

Associazione di livelli di PCR e uso di FANS con gli eventi cardiovascolari

Secukinumab vs TNF-α Blocker bei Enthesitis

Osteoporose bei PsA

Upadacitinib bei PsA

Anämie bei PsA ist ein Thema - effektive Therapie möglich!

Schmerz ist nicht gleich Schmerz: Unterschied von IL-17- und TNF-Inhibition

PET-CT zur Quantifizierung der Entzündung

Gelenkergüsse und Enthesitis nach körperlicher Belastung

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Datos de RM en APs axial

Axial PsA MRI data

JAK inhibitors - new kids on the block

Self-monitoring of disease activity with a smartphone app is feasible in routine clinical management

Dose tapering of TNF inhibitors in axSpA

Inhibidores JAK: nuevas dianas en EspAax

Datos de RM en APs axial

Optimización de iTNF en EspAax

l’auto-monitoraggio di malattia è fattibile nella gestione clinica di routine nei pazienti con Spondiloartrite assiale

Not yet a new standard: belimumab + rituximab

JAKi baricitinib successfully mastered phase II study

JAK-Inhibitor Baricitinib in Phase II erfolgreich

Kombination Belimumab und Rituximab noch kein neuer Standard

A new therapeutic approach for giant cell arteritis?

PET as a predictor of vascular damage in large-vessel vasculits

Secukinumab in giant cell arteritis

Baricitinib in relapsing giant cell arteritis

Neuer Therapieansatz für die Riesenzellarteriitis?

Il ruolo della PET nel predire il danno vascolare nelle vasculiti dei grandi vasi

Baricitinib nell'arterite a cellule giganti recidivante

Secukinumab nell'arterite a cellule giganti

Immune responses to COVID-19 vaccines

Analysis of COVID-19 infection among vaccinated patients with rheumatic disease

Anticytokine antibodies causing severe microbacterial infection

Breakthrough infections after SARS-CoV2-vaccination - national cohort

Breakthrough infections after SARS-CoV2-vaccination - global registry

Impact of COVID-19 on patients with rheumatic diseases

Should we use ultra-low-dose rituximab during the pandemic?

TNF blockers reduce the antibody response to RNA vaccination

Booster with which one if there is no seroconversion?

Vaccination against Delta variant worse in patients treated with TNF-alpha blocker

Durchbruchsinfektionen nach SARS-CoV2-Impfung - globales Register

TNF-Blocker reduzieren Antikörperantwort bei RNA-Impfung

Schlechtere Neutralisation der Delta-Variante unter TNF-alpha Blockern

Womit boostern bei fehlender Serokonversion?

Immunresponser til COVID-19 vaksiner

Durchbruchsinfektionen nach SARS-CoV2-Impfung - nationale Kohorte

Skin findings in patients of color with rheumatic disease

Pearls and myths in rheumatology

CBD - an alternative therapy for chronic pain

New exciting data - dietary supplements with vitamin D and omega-3 fatty acids

Therapeutic drug monitoring - a randomized controlled trial (NOR-DRUM B)

PROs from a real-world study on etanercept biosimilar - 1 year follow-up

Neue spannende Daten - Nahrungsergänzung mit Vitamin D und Omega-3-Fettsäuren

Monitorering av legemiddelkonsentrasjoner (Therapeutic drug monitoring, NOR-DRUM B) – en randomiseret kontrollert studie